Introduction
The presence of mutations in the kinase domain of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients has been regarded as a predictive marker of good response to tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Nearly 90% of these mutations occur as either multinucleotide in-frame deletions in exon 19 or as single missense mutations that result in substitution of arginine for leucine at position 858 (L858R) in exon 21. However, after a median of approximately 10 months from the onset of TKI treatment, some patients whose tumors were initially sensitive to EGFR-TKIs have eventually developed acquired resistance. 1−3 Test of biopsied tumor after disease progression has shown that half of these TKI-resistant cases contained a second site mutation in the EGFR kinase domain. 4−6 The most common alteration involves a C-T (cytosine to thymine) change at nucleotide 2369 in exon 20, which results in substitution of methionine for threonine at position 790 (T790M). Cell lines with EGFR T790M mutation have been shown to have a proliferative advantage over wild type (WT) EGFR due to its increased kinase activity and downstream signaling. 7 Mulloy et al 8 showed the EGFR T790M/L858R double mutant exhibits a substantial increase in phosphorylation compared with the EGFR L858R mutant alone. Nevertheless, Oxnard et al 9 and Arcila et al 10 also observed lower growth rate in cell lines harboring both the EGFR exon 19 deletion and T790M mutation compared with cells harboring only the exon 19 deletion. Considering that the current in vitro results have been inconsistent, the impact of primary EGFR T790M mutation on the prognosis of NSCLC patients needs to be studied.
Bell et al 11 reported a family with multiple cases of NSCLC associated with germline EGFR T790M mutation, where four of the six available samples from two patients showed an activating EGFR mutation (L858R, in-frame deletions in exon 19 or G719A). But in another series, EGFR T790M mutation was never found among 237 NSCLC family probands. 7 Thus, the finding of an NSCLC patient with primary concomitant T790M mutation in the kinase domain of EGFR was rare event in the available series. Not much is known about this subset of cases. Here we report the clinicopathological characteristics and clinical outcome of NSCLC patients whose tumor harbored T790M along with an activating EGFR kinase domain mutation, with the aim of identifying the molecular profile of this subset of NSCLC patients.
Materials and methods

Patients and specimen collection
We consecutively enrolled patients with newly diagnosed primary NSCLC between October 2007 and October 2012. All patients provided written informed consent and underwent radical surgery. Eligible patients for this study had to meet the following criteria: review of pathological diagnosis of NSCLC by morphological features and immunohistochemistry staining, confirmed by two pathologists (L Shen and Y Li); sufficient tumor tissue and corresponding normal tissue available for analysis; and patient had not received neoadjuvant treatment. This study was approved by the institutional review board of Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Mutation analysis
After the surgery, samples were divided into two parts: one part was fixed using formalin and embedded with paraffin to make pathological sections; the other part was snap-frozen in liquid nitrogen at the time of resection and stored in liquid nitrogen. Ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) were extracted from tumors and distant histological normal lung, after frozen specimens were dissected into TRIzol ® (Life Technologies Corp, Carslbad, CA, USA primer located to ALK E20R, were designed to amplify all known fusions variants, as previously described). 12 cDNA PCR products were assessed using the Sanger direct sequencing method 13 in the forward and reverse directions. All mutations were verified by analysis of an independent PCR isolate. When combined EGFR mutations were found in the cDNA PCR product, separated genotyping of each exon was performed using DNA PCR product.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) testing (ThermoBrite StatSpin ® ; Abbott Molecular, Abbott Park, IL, USA) was performed on the corresponding formalin-fixed paraffin-embedded specimens matching the frozen specimens used for the RNA/ DNA extraction, for all patients. We used the Vysis LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe (Abbott Laboratories, Abbott Park, IL, USA), and c-met/CEN7q FISH Probe (Abnova Corp, Taipei, Taiwan) to assess the EGFR and c-MET 16 Pathological TNM stages were evaluated in accordance with the seventh edition of the lung cancer staging classification system. 17 Patients were interrogated about disease recurrence and survival information, either in clinic or by telephone every 3 months after the date of diagnosis. Relapse-free survival (RFS) was defined as the time elapsed between diagnosis and the date of relapse or last follow-up visit. Overall survival (OS) was calculated from the date of diagnosis to date of death or last follow-up visit.
statistical analysis
We used percentages for qualitative variables, and mean and standard deviation for quantitative variables. Pearson Χ 2 test or Fisher's exact tests were used to assess the association between two categorical variables. RFS and OS were compared using the Kaplan−Meier method and logrank test. Cox regression was performed for multivariate analysis of survival. All the statistical analyses were performed using SPSS for Windows (version 16.0) (SPSS Inc., Chicago, IL, USA). P values were two tailed for all the tests, and statistical significance was set as P0.05.
Results
Prevalence of EGFR T790M mutation in nsclc
In all, 1,903 patients were eligible for this analysis, including 1,213 adenocarcinomas, 539 squamous carcinomas, 57 adenosquamous carcinomas, 27 large cell carcinomas, and 67 other NSCLC subtypes. A total of 783 patients were found to harbor EGFR mutation, accounting for 41.2% of all the NSCLC cases. Patients harboring EGFR T790M accounted for 2.04% of all the EGFR mutant cases and 0.84% of the total. There were 14 adenocarcinoma patients who were found to harbor a primary concomitant EGFR T790M mutation, accounting for 1.1% of all lung adenocarcinoma cases. Two patients with adenosquamous carcinoma harbored a EGFR T790M mutation, accounting for 3.5% of all adenosquamous cases. Ten patients harbored an EGFR T790M mutation and L858R mutation concurrently. Five patients harbored EGFR T790M mutation and exon 19 inframe deletions concurrently. One patient harbored EGFR T790M, G719S mutations, and PIK3CA E542K mutation concurrently. None of the 16 patients had any other oncogenic driver mutations, including KRAS, HER2, BRAF, and EML4-ALK fusions.
clinicopathological characteristics of nsclc patients harboring EGFR T790M
Primary EGFR T790M mutation occurred in 13 females and three males, ranging in age at diagnosis from 45 to 66 (mean age: 59.3) years. Of these, 93.7% (15 of 16) patients had never smoked. Three tumors were poorly differentiated; the other 13 tumors were moderately differentiated. The number of patients in pathological TNM stages I−IV was 8, 2, 5, and 1, respectively. Among the 16 patients, two had adenosquamous carcinomas, and the other 14 had adenocarcinomas. The majority subtype of adenocarcinoma was acinar (n=6), followed by papillary (n=4), micropapillary (n=2), solid, and adenocarcinoma in situ. Details of the 16 patients harboring the EGFR T790M mutation are listed in Table 1 . There were 54 patients with a tumor harboring EGFR L858R or exon 19 deletions consecutively enrolled. These samples underwent FISH to detect EGFR gene copy number variations. We compared the clinicopathological characteristics between these patients and patients harboring EGFR T790M (Table 2) . (Table S1 ). The follow-up phase of these patients corresponded with that of the 16 patients harboring primary EGFR T790M. We analyzed the RFS and OS data of these three subgroups of patients. The median follow-up phase was 28.6 months for all the patients and 20.2 months for patients with EGFR T790M mutation. Two patients harboring EGFR T790M mutation had received EGFR-TKI treatment: one received gefitinib and had an occurrence of brain metastasis in the sixth month; the other received erlotinib to control the metastasis to the liver. The metastasis in the latter patient was assessed as progressive disease after 2 months of EGFR-TKI treatment. OS was significantly shorter for patients harboring EGFR T790M mutation than it was in patients with exon 19 deletions (logrank P=0.008). The OS was also shorter in patients with EGFR T790M mutation than that in patients harboring an L858R point mutation ( (Figures 1 and 2) .
We also performed a multivariate analysis of survival significance of patients harboring a primary EGFR T790M mutation. Cox regression showed sex, age at diagnosis, smoking history, tumor differentiation, pathological type, EGFR gene copy number variations, and EGFR-TKI therapy had no significant influence on the OS or RFS of these patients.
EGFR gene copy number variations, c-MET amplification, PIK3CA, p-Akt expression in nsclc with EGFR T790M mutation Among the 16 patients harboring EGFR T790M, no c-MET amplification was found. Six of the 16 samples (37.5%) were EGFR−FISH positive, including two (12.5%) with gene amplification and four (25%) with high polysomy. We compared the frequency of EGFR gene copy number variations (Table 2) . Positive PIK3CA and p-Akt expression were observed in four (25%) and eight (50%) of the 16 patients, respectively ( Figure 3) . A total of 108 NSCLC patients without any mutation were consecutively enrolled from May 2009 to October 2012. We compared PIK3CA and p-Akt expression between these patients and the patients harboring EGFR T790M (Table 3) .
Discussion
Compared with classic activating EGFR mutations, such as L858R and exon 19 in-frame deletions, the clinicopathological and molecular characteristics of NSCLC patients harboring primary T790M mutations remain poorly defined. Somatic EGFR T790M is known to occur as a "secondary mutation" in more than 50% of patients in whom acquired resistance to EGFR-TKIs develops. 5, 6 Germline EGFR T790M mutation is rare and considered to be associated with genetic susceptibility to lung cancer, and may underlie familial predisposition to the disease. 11 As far as we know, our study represents the largest investigation for the prevalence, clinicopathological features, molecular correlations, and clinical outcome in pretreated East Asian NSCLC patients harboring EGFR T790M mutation.
We determined that primary EGFR T790M mutation was a rare event in NSCLC patients, and it was mutually exclusive with other well-identified molecular alterations, except for one PIK3CA E542K mutation. Prudkin et al 18 identified two (0.83%) cases harboring the EGFR T790M mutation from 240 patients with lung adenocarcinomas who had never received treatment with EGFR TKIs. Inukai et al 19 found one (0.54%) EGFR T790M mutation in 185 NSCLC patients without EGFR-TKI treatment, using mutant-enriched PCR analysis, but the findings could not be confirmed by direct sequencing. Considering the extremely low prevalence of primary EGFR T790M mutation in NSCLC patients, screening of this mutation in a large cohort is necessary to define the clinicopathological features and molecular correlations.
Gefitinib-sensitizing EGFR mutations, such as L858R and exon 19 in-frame deletions, selectively activate antiapoptosis signaling pathways. 20 Thus, they can enhance the proliferation and the resistance of apoptosis of tumor cell and have been considered to be oncogenic. In our series, primary EGFR T790M mutation was found concomitant with either L858R or exon 19 deletions in 15 (93.8%) samples. And no single EGFR T790M mutation was found. Also, baseline EGFR T790M was proved to be associated with germline molecular alterations. 21 This may indicate that primary T790M mutation alone cannot induce oncogenesis. It can occur before EGFR-TKI treatment because of tumor cell heterogeneity.
A valuable result we found is that patients harboring primary EGFR T790M mutation had significantly shorter OS than that did patients harboring EGFR exon 19 deletions. And the patients harboring EGFR L858R seem to have a longer OS than did the patients with EGFR T790M. It was proven that EGFR T790M may in fact provide a proliferative advantage by increasing kinase activity and downstream signaling. 7, 22 Our findings indicate that primary EGFR T790M mutation might be a predictor for poor prognosis. However, considering the different postoperative treatment strategies these patients received, this finding should be verified. That the RFS was 
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c-MET amplification was considered to be a mechanism for acquired resistance to EGFR-TKIs. This molecular change had been found in samples with gefitinib or erlotinib resistance in vivo or in vitro. 23 c-MET amplification has also occasionally been found to coexist with EGFR T790M mutation. 24 Therefore, we detected this kind of molecular change, using FISH, in the 16 samples harboring EGFR T790M, with an attempt to define the association between these two kinds of TKIresistant-related molecular changes. But we found no c-MET amplification in them. This result may indicate that concurrence of the two kinds of molecular change is a rare event in patients who have not undergone EGFR-TKI treatment.
Some former studies using FISH have proposed EGFR gene copy number variations as an important predictor of response to EGFR-TKIs. 14, 25, 26 In our study, we found a lower frequency of EGFR gene copy number variations in patients harboring EGFR T790M than in patients harboring exon 19 deletions and L858R. This result may confirm that primary EGFR T790M mutation, as a molecular marker, can induce initial resistance to EGFR-TKIs.
To our knowledge, well-defined EGFR-TKI resistance mechanisms share the same potential concept: they enable the cancer cell to maintain its intracellular growth signaling pathways, especially the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) pathway. 20,27−30 In our series, we found 50% of samples had an overexpressed level of p-Akt, but a corresponding overexpression were not found in the upstream protein PIK3CA. Our results may indicate primary EGFR T790M mutation can induce p-Akt expression through other mechanism, which are yet to be revealed.
In summary, our study of a large cohort described the clinicopathological and molecular characteristics of NSCLC patients harboring primary EGFR T790M mutations. Its value of being a predictor for worse prognosis was established. Primary EGFR T790M mutation is indeed a rare molecular change in NSCLC cases, but the therapeutic strategies for this subtype of patients should be carefully considered. 
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